Concepedia

Author

Eberhard Ritz

Heidelberg University

Also Known As

E RITZ, E Ritz, E Ritz,, E. RITZ, E. Ritz, E. Ritz, E.‐M. Jordi Ritz, EBERHARD RITZ, Eberhard RITZ, Eberhard Ritz

1.4K

Publications

61.6K

Citations

111

H-Index

267

Concepts

All Affiliations

Heidelberg UniversityUniversity Hospital HeidelbergFriedrich-Alexander-Universität Erlangen-NürnbergMedical University of Graz
ER

About

Eberhard Ritz is an author at Heidelberg University specializing in medicine, chronic kidney disease, and nephrology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

73

294

20.7K

2

Health Sciences

29

55

2.7K

3

Natural Sciences

3

3

188

4

Arts

2

2

42

5

Engineering

2

2

99

Eberhard Ritz

×

479

Publications

46K

Citations

101

H-Index

YearCitations

Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes

Edmund J. Lewis, Lawrence G. Hunsicker, William R. Clarke,

New England Journal of Medicine

2001

5.9K

Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing Hemodialysis

Christoph Wanner, Vera Krane, Winfried März,

New England Journal of Medicine

2005

2.6K

Effect of the Angiotensin-Converting–Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency

Giuseppe Maschio, Daniele Alberti, G. Janin,

New England Journal of Medicine

1996

1.8K

Nephron Number in Patients with Primary Hypertension

Gunhild Keller, Gisela Zimmer, Gerhard Mall,

New England Journal of Medicine

2003

1.1K

Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)

Charles A. Herzog, Richard Asinger, Alan K. Berger,

Kidney International

2011

908

Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes

Hermann Haller, Sadayoshi Ito, Joseph L. Izzo,

New England Journal of Medicine

2011

784

Association of a human G-protein β3 subunit variant with hypertension

Winfried Siffert, Dieter Rosskopf, G Siffert,

Nature Genetics

1998

730

Fibroblast Growth Factor 23 (FGF23) Predicts Progression of Chronic Kidney Disease

Danilo Fliser, Barbara Kollerits, Ulrich Neyer,

Journal of the American Society of Nephrology

2007

688

Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial

Dick de Zeeuw, Rajiv Agarwal, Michael Amdahl,

The Lancet

2010

686

Combining GFR and Albuminuria to Classify CKD Improves Prediction of ESRD

Stein Hallan, Eberhard Ritz, Stian Lydersen,

Journal of the American Society of Nephrology

2009

444

Page 1